Program

Agenda for Best of ASCO 2024 in Qatar

6 and 7 September 2024

“The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators, and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.”

Learning Outcomes:

The learning objectives of the Best of ASCO 2024 in Qatar are that participants will be appraised of the latest expert consensus thinking and the most prescient research findings for the treatment and management of common and rare cancers.

Specifically, participants will be able:

  • To enable HMC cancer professionals to identify the latest research findings and evaluate the implications for treatment options for common tumors such as breast, colon, lung, and prostate cancers.
  • To identify the latest research findings and evaluate the implications for the care and management of rare cancers such as neurological, head and neck, urological, gynecology and sarcoma.
  • To identify and evaluate the implications for HMC cancer practice and cancer research of advances of emergent developmental therapeutics such as immunotherapy, molecular precision medicine and tumor biology.
  • To identify and evaluate the latest approaches to symptom management and survivorship to shape HMC cancer service development and improvement.​